NervGen Pharma Corp. (NGEN)
NASDAQ: NGENHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NGEN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $198.55M
- EPS (TTM)
- -$0.24
- Dividend yield
- None
- 52-week range
- 1.28 – 6.30
- Day range
- 1.83 – 1.96
- Volume / Avg
- 661.48K / 621.66K
- Beta
- —
- Shares outstanding
- 107.62M
52-week range
NGEN stock today
Shares of NervGen Pharma (NGEN) finished lower on Nov 20 at $1.85, a drop of 3.91% or $0.075 per share, versus the S&P 500's 3.70% decline. At this level, NGEN sits near the bottom of its 52-week range of $1.28 to $6.30: 70.7% below the high, set on Jan 8, 2026 and 44.1% above the low. NGEN is down 67.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 35.0%.
NervGen Pharma has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About NervGen Pharma
Company profileNervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Adam H. Rogers M.D.
- Headquarters
- Vancouver, BC
- Employees
- 9
- Website
- nervgen.com
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$10.00+442.01%
- Strong buy 2
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.04 vs $0.01
- Surprise
- -500.00%
NGEN news
All NGEN news- NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical OfficerGlobeNewswire
- NervGen Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire
- NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord InjuryGlobeNewswire
- NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord InjuryGlobeNewswire
NervGen Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BIOABioAge Labs Inc. | 4.28 | -9.13% | $196.67M | vs NGEN |
| YARWYarrow Bioscience Inc. | 12.90 | -9.35% | $196.53M | vs NGEN |
| DRUGBright Minds Biosciences Inc. | 20.40 | -1.45% | $201.23M | vs NGEN |
| ACIUAC Immune SA | 1.95 | -8.45% | $193.88M | vs NGEN |
| BCYCBicycle Therapeutics plc ADR | 2.90 | -4.92% | $203.27M | vs NGEN |
| FTHFaeth Therapeutics Inc. | 7.88 | -9.32% | $203.65M | vs NGEN |
| ANTXAN2 Therapeutics Inc. | 5.08 | -2.68% | $192.75M | vs NGEN |
| VNDAVanda Pharmaceuticals Inc. | 3.45 | -6.13% | $208.32M | vs NGEN |
Indexes, lists and sector
NervGen Pharma stock FAQ
What is NervGen Pharma's stock price today?
NGEN last traded at $1.85 as of Nov 20, 4:00 PM EST, down 3.91% on the day. Prices are delayed at least 15 minutes.
Who is NervGen Pharma's CEO?
Dr. Adam H. Rogers M.D. is the chief executive officer of NervGen Pharma Corp., which has about 9 employees.
What is the NGEN 52-week high?
The 52-week high for NGEN is $6.30 and the 52-week low is $1.28. The stock is currently 70.7% below its high.